Automated Trading Based on Deep-Learning: Returns up to 47.35% in 3 Months

Automated Trading

This forecast is part of the Top 10 Stocks Package, as one of I Know First’s systematic trading tools. The full package includes a daily prediction for a total of 20 stocks with bullish and bearish signals:

  • Top 10 stocks pick for the long position
  • Top 10 stocks pick for the short position


Package Name: Top 10 Stocks
Recommended Positions: Short
Forecast Length: 3 Months (09/18/2018 – 12/18/2018)
I Know First Average: 22.62%
Automated Trading

10 out of 10 top stock picks from the algorithm decreased as predicted for this long-term forecasting period. LGND saw monumental growth of 47.35% in just 3 Months. NBIX, and SGMS also had excellent performances with returns of 39.27% and 33.94% respectively. The package had an overall average return of 22.62%, providing investors with a premium of 34.48% over the S&P 500’s return of -11.86% during the same period.

Ligand Pharmaceuticals Incorporated (Ligand), incorporated on September 28, 1987, is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work towards obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. The Company is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.